Antenatal Steroids Pose Long-Term Neurodevelopmental Risks

A group of maternal-fetal medicine specialists and neonatologists has published a stark commentary on the use of antenatal corticosteroids. The drugs, administered to pregnant people at risk of preterm birth to accelerate fetal lung development, may carry significant long-term neurodevelopmental risks for children. The authors, writing in a Wiley journal, argue that the medical community faces a profound ethical dilemma between preventing immediate respiratory distress and potentially causing lasting harm.

The Established Benefit and Emerging Risk

The use of antenatal corticosteroids, primarily betamethasone and dexamethasone, is a cornerstone of modern obstetrics for impending preterm birth. The treatment's benefit in reducing neonatal respiratory distress syndrome and mortality is well-established, stemming from a landmark 1972 trial. However, the commentary synthesizes a growing body of evidence suggesting this short-term gain comes with a long-term price. Recent large-scale population studies indicate an association between antenatal corticosteroid exposure and an increased risk of psychological, developmental, and neurosensory disorders in children.

Specifically, the authors cite research linking the treatment to higher rates of childhood mental and behavioral disorders, neurodevelopmental disorders, and even serious childhood infections. One cited study in the Journal of Pediatrics found the association held for mental disorders in children born both late preterm and at term. "We are trading a short-term benefit for a long-term risk," the commentary implies, framing a troubling risk-benefit calculation that has evolved since the therapy's introduction.

The Late Preterm Dilemma

The ethical quandary is particularly acute for births in the late preterm period, between 34 and 36 weeks of gestation. This group represents the largest population exposed to these steroids, following influential trials like the ALPS study which supported their use for late preterm delivery risk. The commentary notes that most infants given steroids for threatened late preterm birth are ultimately born at term, meaning they received the medication without the anticipated indication of prematurity. A 2023 systematic review cited in the source found that for every 17 people treated for potential late preterm birth, only one actually delivered in that window.

This leads to a significant treatment-to-delivery interval mismatch, exposing many fetuses to steroids without the justifying condition of early birth. The authors question whether the reduction in short-term respiratory problems, which are generally less severe in late preterm infants, outweighs the potential for inducing lifelong neurodevelopmental challenges in a much larger number of children.

Biological Mechanisms and Lasting Effects

Emerging laboratory science is beginning to explain how a brief exposure in utero could have lifelong consequences. The commentary points to preclinical research using human brain organoids, which are lab-grown cell models that mimic brain development. These studies suggest that glucocorticoids (the class of drug that includes these steroids) can chronically alter the developmental trajectory of the brain. They may amplify the production of inhibitory neurons and create an enduring imbalance between neural excitation and inhibition.

This biological mechanism provides a plausible pathway for the neurodevelopmental and psychiatric disorders observed in epidemiological studies. The effects may not be confined to early childhood. The authors reference a 2024 follow-up study of adults exposed to betamethasone before birth, which found they had poorer general health and social outcomes 50 years later. The source states this indicates the impact of antenatal corticosteroids "may extend across the entire life course."

Global Guidelines and Unanswered Questions

Practice guidelines have struggled to keep pace with this evolving evidence. The World Health Organization recommends antenatal corticosteroids for early preterm birth, even in low-resource settings, but the commentary highlights a critical lack of long-term safety data from those populations. Also, not all steroid formulations may be equal. The authors cite animal research indicating that a common betamethasone preparation containing both acetate and phosphate salts may be less effective and associated with lower birth weights than the acetate-only form.

Individual genetic variation in response to the steroids is another layer of complexity, mentioned as an area of ongoing research. The overarching message is that the clinical decision is no longer straightforward. The commentary calls for more nuanced counseling, acknowledging the long-term uncertainties, and for a concerted international research effort. It notes the establishment of the Consortium for the Study of Pregnancy Treatments (Co-OPT), a dedicated birth cohort designed to finally provide comprehensive long-term safety data. For now, clinicians and pregnant patients are left to handle a choice with implications that may span generations.